Home/Pipeline/Senhance® for Oncology

Senhance® for Oncology

Robotic Surgery in Oncological Procedures

Clinical ExpansionFeasibility Studies Published

Key Facts

Indication
Robotic Surgery in Oncological Procedures
Phase
Clinical Expansion
Status
Feasibility Studies Published
Company

About Asensus Surgical

Asensus Surgical is revolutionizing minimally invasive surgery by developing and commercializing the Senhance® Surgical System, a robotic platform integrated with the first globally approved intra-operative augmented intelligence system. The company focuses on reducing surgical variability, improving surgeon ergonomics, and increasing accessibility through reusable instruments and a lower-cost model. Following its acquisition by KARL STORZ, Asensus is positioned to accelerate the global adoption of its digital surgery technology, aiming to set a new standard of care in robotic-assisted procedures.

View full company profile